Cme Group annual cash and equivalents
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Cme Group Cash & Equivalents Growth & History (CME)
Cme Group's cash and equivalents was $4.42B for fiscal 2025.
View full Cme Group company overviewCme Group annual cash and equivalents history
| Fiscal year | Period ended | Cash and equivalents | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $4.42B | $1.52B | +52.71% |
| 2024 | 2024-12-31 | $2.89B | −$19.6M | −0.67% |
| 2023 | 2023-12-31 | $2.91B | $191.9M | +7.05% |
| 2022 | 2022-12-31 | $2.72B | −$114.8M | −4.05% |
| 2021 | 2021-12-31 | $2.83B | $1.20B | +73.58% |
| 2020 | 2020-12-31 | $1.63B | $81.8M | +5.27% |
| 2019 | 2019-12-31 | $1.55B | $176.9M | +12.87% |
| 2018 | 2018-12-31 | $1.37B | −$529.1M | −27.79% |
| 2017 | 2017-12-31 | $1.90B | $35.0M | +1.87% |
| 2016 | 2016-12-31 | $1.87B | $176.0M | +10.40% |
| 2015 | 2015-12-31 | $1.69B | $326.5M | +23.90% |
| 2014 | 2014-12-31 | $1.37B | −$1.10B | −44.69% |
| 2013 | 2013-12-31 | $2.47B | $865.0M | +53.90% |
| 2012 | 2012-12-31 | $1.60B | $562.4M | +53.96% |
| 2011 | 2011-12-31 | $1.04B | $187.1M | +21.88% |
| 2010 | 2010-12-31 | $855.2M | $594.6M | +228.17% |
| 2009 | 2009-12-31 | $260.6M | −$37.3M | −12.52% |
| 2008 | 2008-12-31 | $297.9M | −$547.4M | −64.76% |
| 2007 | 2007-12-31 | $845.3M | — | — |
Cme Group quarterly cash and equivalents
Q4.08
Q2.09
Q3.09
Q4.09
Q1.10
Q2.10
Q3.10
Q4.10
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Cash and equivalents | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $2.14B | $162.9M | +8.22% |
| Q1 2026 | 2026-03-31 | $2.39B | $985.9M | +70.16% |
| Q4 2025 | 2025-12-31 | $4.42B | $1.52B | +52.71% |
| Q3 2025 | 2025-09-30 | $2.45B | $124.7M | +5.37% |
| Q2 2025 | 2025-06-30 | $1.98B | $191.4M | +10.69% |
| Q1 2025 | 2025-03-31 | $1.41B | −$31.6M | −2.20% |
| Q4 2024 | 2024-12-31 | $2.89B | −$19.6M | −0.67% |
| Q3 2024 | 2024-09-30 | $2.32B | $21.9M | +0.95% |
| Q2 2024 | 2024-06-30 | $1.79B | −$90.2M | −4.80% |
| Q1 2024 | 2024-03-31 | $1.44B | −$128.3M | −8.20% |
| Q4 2023 | 2023-12-31 | $2.91B | $191.9M | +7.05% |
| Q3 2023 | 2023-09-30 | $2.30B | $170.1M | +7.99% |
| Q2 2023 | 2023-06-30 | $1.88B | $600,000 | +0.03% |
| Q1 2023 | 2023-03-31 | $1.57B | −$480.5M | −23.49% |
| Q4 2022 | 2022-12-31 | $2.72B | −$114.8M | −4.05% |
| Q3 2022 | 2022-09-30 | $2.13B | $670.7M | +45.96% |
| Q2 2022 | 2022-06-30 | $1.88B | $798.5M | +73.87% |
| Q1 2022 | 2022-03-31 | $2.05B | $1.11B | +118.46% |
| Q4 2021 | 2021-12-31 | $2.83B | $1.20B | +73.58% |
| Q3 2021 | 2021-09-30 | $1.46B | $127.3M | +9.56% |
| Q2 2021 | 2021-06-30 | $1.08B | −$324.4M | −23.08% |
| Q1 2021 | 2021-03-31 | $936.4M | $84.7M | +9.94% |
| Q4 2020 | 2020-12-31 | $1.63B | $81.8M | +5.27% |
| Q3 2020 | 2020-09-30 | $1.33B | $122.0M | +10.08% |
| Q2 2020 | 2020-06-30 | $1.41B | $467.7M | +49.88% |
| Q1 2020 | 2020-03-31 | $851.7M | −$145.7M | −14.61% |
| Q4 2019 | 2019-12-31 | $1.55B | $176.9M | +12.87% |
| Q3 2019 | 2019-09-30 | $1.21B | −$196.2M | −13.95% |
| Q2 2019 | 2019-06-30 | $937.7M | −$161.2M | −14.67% |
| Q1 2019 | 2019-03-31 | $997.4M | $212.8M | +27.12% |
| Q4 2018 | 2018-12-31 | $1.37B | −$529.1M | −27.79% |
| Q3 2018 | 2018-09-30 | $1.41B | −$224.8M | −13.78% |
| Q2 2018 | 2018-06-30 | $1.10B | −$263.4M | −19.33% |
| Q1 2018 | 2018-03-31 | $784.6M | −$503.2M | −39.07% |
| Q4 2017 | 2017-12-31 | $1.90B | $35.0M | +1.87% |
| Q3 2017 | 2017-09-30 | $1.63B | $210.6M | +14.83% |
| Q2 2017 | 2017-06-30 | $1.36B | $201.2M | +17.33% |
| Q1 2017 | 2017-03-31 | $1.29B | $141.8M | +12.37% |
| Q4 2016 | 2016-12-31 | $1.87B | $176.0M | +10.40% |
| Q3 2016 | 2016-09-30 | $1.42B | −$13.8M | −0.96% |
| Q2 2016 | 2016-06-30 | $1.16B | $10.1M | +0.88% |
| Q1 2016 | 2016-03-31 | $1.15B | −$548.8M | −32.38% |
| Q4 2015 | 2015-12-31 | $1.69B | $326.5M | +23.90% |
| Q3 2015 | 2015-09-30 | $1.43B | $346.4M | +31.84% |
| Q2 2015 | 2015-06-30 | $1.15B | $113.7M | +10.96% |
| Q1 2015 | 2015-03-31 | $1.69B | $641.1M | +60.84% |
| Q4 2014 | 2014-12-31 | $1.37B | −$1.10B | −44.69% |
| Q3 2014 | 2014-09-30 | $1.09B | −$977.1M | −47.32% |
| Q2 2014 | 2014-06-30 | $1.04B | −$930.7M | −47.29% |
| Q1 2014 | 2014-03-31 | $1.05B | −$789.7M | −42.84% |
| Q4 2013 | 2013-12-31 | $2.47B | $865.0M | +53.90% |
| Q3 2013 | 2013-09-30 | $2.06B | $48.1M | +2.38% |
| Q2 2013 | 2013-06-30 | $1.97B | $674.8M | +52.18% |
| Q1 2013 | 2013-03-31 | $1.84B | $781.7M | +73.63% |
| Q4 2012 | 2012-12-31 | $1.60B | $562.4M | +53.96% |
| Q3 2012 | 2012-09-30 | $2.02B | $1.19B | +143.21% |
| Q2 2012 | 2012-06-30 | $1.29B | $599.6M | +86.45% |
| Q1 2012 | 2012-03-31 | $1.06B | $397.0M | +59.73% |
| Q4 2011 | 2011-12-31 | $1.04B | $187.1M | +21.88% |
| Q3 2011 | 2011-09-30 | $829.3M | $261.1M | +45.95% |
| Q2 2011 | 2011-06-30 | $693.6M | $330.0M | +90.76% |
| Q1 2011 | 2011-03-31 | $664.7M | $220.5M | +49.64% |
| Q4 2010 | 2010-12-31 | $855.2M | $594.6M | +228.17% |
| Q3 2010 | 2010-09-30 | $568.2M | $364.1M | +178.39% |
| Q2 2010 | 2010-06-30 | $363.6M | −$85.1M | −18.97% |
| Q1 2010 | 2010-03-31 | $444.2M | — | — |
| Q4 2009 | 2009-12-31 | $260.6M | −$37.3M | −12.52% |
| Q3 2009 | 2009-09-30 | $204.1M | — | — |
| Q2 2009 | 2009-06-30 | $448.7M | — | — |
| Q4 2008 | 2008-12-31 | $297.9M | — | — |
Cme Group cash and equivalents trends
Over the last five fiscal years, Cme Group's cash and equivalents increased from $1.63B to $4.42B, a change of $2.78B. The latest reported quarter, Q2 2026, shows $2.14B.
About the metric
What cash and equivalents mean
Cash and cash equivalents, often described as cash on hand, are highly liquid resources available for near-term obligations, investment, acquisitions, debt repayment, dividends, or share repurchases. This measure does not include short-term investments reported separately.
Calculation and source
Reported cash and equivalents
TickerStat standardizes cash and cash equivalents reported on the balance sheet. Restricted cash is included only when the company reports it within the selected consolidated cash concept. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Cme Group source filings ↗Community posts
CME plans European dairy futures and options through EEX transition
CME Group ($CME) agreed with the European Energy Exchange to transition EEX’s European dairy business, including its butter and skimmed-milk-powder indices, as EEX phases out those products. CME plans to establish its own European dairy ind ...
CME sets an FX open-interest record of 4.41 million contracts
CME Group reported a new foreign-exchange derivatives milestone on 7 September 2026. Reported records FX futures and options open interest reached 4,410,167 contracts on 4 September, exceeding the previous 4,269,622 record from 11 June. Tha ...